BLAINJECTIONINJECTABLEPriority Review
Approved
Apr 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
13
Data completeness
3/8 — Basic
Priority Review
SYLVANT (siltuximab) by Recordati is interleukin-6 antagonists [moa]. First approved in 2014.
Drug data last refreshed 8h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SYLVANT (siltuximab) is a chimeric monoclonal antibody that antagonizes interleukin-6 (IL-6), a key cytokine driver of inflammation. It is approved for multicentric Castleman disease (MCD), a rare lymphoproliferative disorder characterized by systemic inflammation. By blocking IL-6 signaling, siltuximab reduces inflammatory cytokine production and associated symptoms.
Peak
SYLVANT operates in peak lifecycle with moderate competitive pressure (30/100), suggesting a stable but specialized rare-disease franchise requiring focused commercial and medical affairs engagement.
Mechanism of Action
Interleukin-6 Antagonists
Pharmacologic Class:
Interleukin-6 Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (13)
Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
Started Jan 2025
20 enrolled
Non-Hodgkin LymphomaCytokine Release Syndrome
A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant
Started Nov 2024
215 enrolled
Multiple Myeloma
Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
Started Nov 2021
20 enrolled
Cytokine Release SyndromeICANSLymphoma, Non-Hodgkin+2 more
Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease
Started Mar 2021
22 enrolled
Idiopathic Multicentric Castleman's Disease
SILtuximab in Viral ARds (SILVAR) Study
Started Nov 2020
555 enrolled
Acute Respiratory Distress SyndromeLung DiseasesPneumonia+2 more
Worked on SYLVANT at Recordati? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.